bero L, Carreras E ;Pesario Cervical para Evitar Prematuridad(PECEP)Trial Group. Cervical pessary in pregnant women with a short cervix(PECEP) : an open-label randomised controlled trial. Lancet 2012:379巧828):1800-1806.
[0185] Grazzini E,Guillon G,Mouillac B, Zingg HH.Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 1998 ; 392巧675):509-12.
[0186] Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pi1lay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko 0, Kinzler W, Dattel B, Sehdev H, Mazheika L,Manchulenko D,Gervasi MT,Sullivan L, Conde-Agudelo A,Phillips JA, Creasy GW. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix:a multicenter,randomized,double-blind,placebo-control led trial. Ultrasound ObstetGynecol 2011:38(1):18 - 31.
[0187] Heath VC, Southall TR, Souka AP, Elisseou A, Nicolaides KH. Cervical length at 23 weeks of gestationiprediction of spontaneous preterm delivery. Ultrasound ObstetGynecol 1998 :12:312 - 317.
[0188] lams JD, Goldenberg肥,Meis PJ, y cols, and化e National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med 1996;334:567 - 72.
[0189] lams JD,民omero民,Culhane JF, Goldenberg民L. Primary, secondary, and tertiary interventions to reduces the morbidity and mortality of preterm birth. Lancet 2008 :371:164-175.
[0190] Jayasooriya, GS and Lamont,民F. The use of progesterone and other progestational agents to prevent spo打ta打eous preterm labour a打d preterm birth. Expert Opin. Pharmaco化er. 2009, 10巧):1007-1016.
[0191] Marlow化Wolke D, Bracewell M, Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005 ; 352:9-19.
[0192] Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacher F, Munson MLBirths:final data for 2002. Natl Vital Stat Rep 2003 :52:1 - 113.
[0193] Menon民.Spontaneous preterm birth, a clinical dilemma:etiologic, pathop hysiologic and genetic heterogeneities and racial disparity. ActaObstetGynecol Scand. 2008 ;87 (6) :590-600.
[0194] Owen J, Yost N, Berghella V,Thom E, Swain M, Dildy GA, III,Miodovnik M, Langer 0,Sibai B, McNellis D. Mid-trimester endovaginal sonography in women at hi組risk for spontaneouspreterm bii'th. JAMA 2001 :286:1340 - 1348.
[0195] Romero民,Espinoza J, Erez 0, Hassan S. The role of cervical cerclage in obstetric practice:can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol. 2006:194:1-9.
[0196] Romero民.Vaginal progesterone to reduce the rate of preterm birth and neonatal morbidity:a solution at last. Women> s Health 2011 ;7巧):501-504.
[0197] Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008;371:261-269.
[0198] Simcox R, Seed PT, Bennett P, Teoh TG, Poston L, Shennan AH. A randomized controlled trial of cervical scanning vs history to determine cerclage in women at hi組risk of preterm bii'tMCIRCLE trial).Am J ObstetGynecol 2009:200:623. el-6.
[0199] Souka AP, Hea化V,F(xiàn)lint S, Sevastopoulou I,Nicolaides KH. Cervical length at 23 weeks in twins in predicting spontaneous preterm delivery. ObstetGynecol 1999;94:450 - 454
[0200] To MS, Skentou CA, Royston P,化CK, Nicolaides KH. Prediction of patient-specific risk of early preterm delivery using maternal history and sonographic measurement of cervical length:a population-based prospective s化dy. Ultrasound ObstetGynecol 2006;27:362-367.
【主權(quán)項(xiàng)】
1. 環(huán)扎子宮托,其特征在于由包含均勻分布在整個(gè)子宮托體的孕酮的二甲基硅氧烷彈 性體組成,孕酮的含量為20重量%至30重量%子宮托總重,孕酮延長(zhǎng)、保持不變和持續(xù)釋 放至少6個(gè)月的時(shí)間段,子宮托在全部時(shí)間保持完整。2. 根據(jù)權(quán)利要求1的子宮頸子宮托,其特征在于子宮托中的孕酮含量為5. 0g至 10. 5g〇3. 根據(jù)權(quán)利要求1的子宮頸子宮托,其特征在于具有25至35克的重量。4. 根據(jù)權(quán)利要求1的子宮頸子宮托,其特征在于從子宮托保持不變和持續(xù)釋放的孕酮 含量為每天15mg至65mg,持續(xù)至少6個(gè)月的時(shí)間段。5. 根據(jù)權(quán)利要求1的子宮頸子宮托,其特征在于彈性體由乙烯基-聚二甲基硅氧烷聚 合物、無(wú)定形硅石和鉑催化劑以及二甲基甲基氫硅氧烷和聚二甲基硅氧烷的共聚物形成。6. 根據(jù)權(quán)利要求1至5的子宮頸子宮托,其特征在于彈性體由6:1至14:1的聚合物比 例形成。7. 根據(jù)權(quán)利要求1的子宮頸子宮托的用途,其特征在于用于制備用于預(yù)防早產(chǎn)的藥 物。
【專(zhuān)利摘要】含有均勻分布在子宮托體中的孕酮的環(huán)扎子宮托提供了延長(zhǎng)、保持不變和持續(xù)的釋放,持續(xù)至少6個(gè)月的時(shí)間段,其中子宮托由具有RTV(室溫硬化)機(jī)理的二甲基硅氧烷彈性體組成,孕酮含量為20%至30%w/w,相對(duì)于子宮托重量,并且形成基質(zhì)的聚合物的比例為6:1至14:1。環(huán)扎子宮托用于預(yù)防早產(chǎn)。由于本文中所用的形成聚合物基質(zhì)的彈性體不是生物可降解的,孕酮通過(guò)聚合物持續(xù)擴(kuò)散,沒(méi)有改變子宮托的形狀和完整性。這確保了子宮托的形式保持完整,直至治療結(jié)束。
【IPC分類(lèi)】A61F6/08
【公開(kāi)號(hào)】CN105392454
【申請(qǐng)?zhí)枴緾N201480001890
【發(fā)明人】G·A·坎波斯佩雷斯, 陳淑真
【申請(qǐng)人】安德羅瑪克實(shí)驗(yàn)室股份有限公司
【公開(kāi)日】2016年3月9日
【申請(qǐng)日】2014年6月28日
【公告號(hào)】CA2873222A1, EP2982352A1, WO2015198104A1